A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients

Indian Journal of Pharmacology

Volumn 42, Issue 6, 2010, Pages 362-365

  Jothi, R ^a   Ismail, A M ^b   Senthamarai, R ^b   Pal, Siddhartha ^b  

^a RVS College of Pharmaceutical Sciences   (India)

^b Periyar College of Pharmaceutical Sciences for Girls   (India)

Author keywords

Bimatoprost timolol; dorzolamide timolol; intraocular pressure; ocular hypertension

Indexed keywords

BIMATOPROST PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL;

ADULT; ARTICLE; BROWACHE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EYE BURNING; EYE DISEASE; EYE IRRITATION; EYE PAIN; EYE REDNESS; FEMALE; FOREIGN BODY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PIGMENT GLAUCOMA; PSEUDOEXFOLIATIVE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT RESPONSE;

EID: 78149383713     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.71917     Document Type: Article

References (14)

1. Dong HS, Robert MF, Wang-Pui S. Efficacy and Safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocularpressure. J Ophth 2004;111:276-82.
2. Constance N, Richard KL. Glaucoma screening: Current trends, Economic issues, Technology and Challenges. Curr Opin Ophthalmol 2006;17:142-52.
3. Joseph TD, Robert LT, Gary CY, Gary RM, Barbara GW, Michale PA. Text book of Pharmacotherapy, A Pathophysiologic approach. 5th ed. New York: McGraw-HILL Medical Publishing Division; 2002. p. 1665-7.
4. Quigley H, Broman HT. The number of People with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7.
5. Gupta SK, Galpalli ND, Agrawal SS, Rohit S. Recent advances in Pharmacotherapy of glaucoma. Indian J Pharmacol 2008;40:197-08.
6. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
7. Ritch R. Natural compounds: Evidence for a protective role in eye disease. Can J Ophthalmol 2007;42:425-38.
8. Remo SJ, Wang-Pui S. Comparison of latanoprost with fixed -combination dorzolamide and timolol in adult patients with elevated intraocular pressure: An eighth-week, randomized, open-label, parallel-group, multi center study in Latin America. Clin Ther 2004;26:755-6.
9. James DB, Louis BC, Jay K, Amy LB, Connie C, Izabella B. Bimatoprost/Timolol fixed combination: A 3 - month, double masked, randomized parellel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008;17:211-6.
10. Martinez A, Sanchez M. Intraocular pressure lowering effect of dorzolamide/ timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides. Curr Med Res Opin 2007;23:595-9.
11. Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453-7.
12. Cvenkle B, Stewart JA, Nelson LA, Stewart WC. Dorzolamide/tiomolol fixed combination versus Latanoprost/ tiomolol fixed combination in patients with primary open-angle glaucoma or ocular hyprtension. Curr Eye Res 2008;13:163-8.
13. Ronald EP, Max F, Allision T. Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or Ocular hypertension. BMC Ophthalmol 2007;7:15-20.
14. Tuil E, Hommer AB, Poulsen PB, Christensen TL, Buchholz JW, Holmstrom S. The cost - effectiveness of Bimatoprost 0.03% in the treatment of glaucoma in adult patients: A European perspective. Int J Clin Pract 2005;59:1011-6.